Occam Places CSO of ADC Biotech MBrace Therapeutics
In March 2024, Occam recruited Steve Alley, PhD, as Chief Scientific Officer for MBrace Therapeutics, a Venrock, TPG, and Cowen investment.
Alley joins MBrace Therapeutics after serving as the Executive Director of Translational Sciences at Seagen. During his tenure at Seagen, Alley played a crucial role in the company's rapid growth by assuming various leadership positions in research and development. Alley led the bioanalysis and DMPK groups, contributed to developing Seagen's ADC technology platform, and led the cross-functional team that discovered the Seagen Sugar Engineered Antibody technology platform.
MBrace was founded in 2020 by CEO Isan Chen, M.D.,formerly CMO of Mirati Therapeutics; Renata Pasqualini, Ph.D.; and Wadih Arap, M.D./Ph.D. MBrace is a clinical-stage biopharmaceutical company developing innovative ADC cancer therapeutics utilizing the SPARTA technology pioneered by its founders.
Related Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.